RxDoctor Payments Data

Linda Bartell, MD

Internal Medicine · Fresno, CANPI 1568458966

Payments from drug & device makers

$1,657in general payments, 2019–2025

Across 89 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$295
  • Pfizer$196
  • Lilly USA, LLC$171
  • Johnson & Johnson$140
  • Astellas Pharma US Inc$127
  • Biohaven Pharmaceuticals, Inc.$126
  • plus $602 from 12 others

What the payments were for

  • Food & beverage$1,55794%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,657 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$171,830
Medicare patients
382
Services billed
2,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$50,631
XareltoRivaroxaban28$38,119
JanuviaSitagliptin Phosphate26$35,951
EliquisApixaban24$35,586
MounjaroTirzepatide21$20,351
Breo ElliptaFluticasone/Vilanterol12$9,293
SynthroidLevothyroxine Sodium51$5,369
Levothyroxine Sodium447$4,425
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,484
Estradiol66$3,264
PremproEstrogen,con/M-Progest Acet13$2,984
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen112$2,607
Estradiol (Twice Weekly)Estradiol22$2,594
Metoprolol Succinate113$2,200
Ezetimibe33$1,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$25$50,63141 claims
PfizerEliquis, Prempro$196$38,57037 claims
Johnson & JohnsonXarelto$140$38,11928 claims
Lilly USA, LLCMounjaro$171$20,35121 claims
GSKBreo Ellipta$35$9,29312 claims
AbbVieSynthroid$91$5,36951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →